Predictors of Discontinuation of Angiotensin Converting Enzyme Inhibitors Use Among Medicare Beneficiaries Using Sodium-Glucose Cotransporter 2 Inhibitors - PubMed
3 hours ago
- #Medicare
- #ACEi
- #SGLT2i
- Approximately 25.4% of ACEi users discontinued therapy within 1 year of SGLT2i initiation.
- Higher discontinuation risk was associated with ACEi initiation at or after SGLT2i initiation, ARB use, acute myocardial infarction, stroke/TIA, and Black or Hispanic ethnicity.
- Lower discontinuation risk was linked to older age (65-75) and metformin use.
- Discontinuation rates were higher among Hispanic (35.1%) and Black (33.9%) patients compared to White patients (24.0%).
- The study highlights the need for individualized strategies to support persistence with cardioprotective therapies in T2D care.